Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Files Shelf Registration to Offer up to $150M

NEW YORK (GenomeWeb News) – Trovagene this week filed a shelf registration with the US Securities and Exchange Commission for the public offering of up to $150 million in securities from time to time.

A spokesperson for the San Diego-based molecular diagnostic firm said the filing is associated with a public offering that the company made in the spring of 2012 when it began trading its stock on the Nasdaq.

Proceeds from any offering associated with this week's filing will go toward general corporate purposes, including working capital, R&D, clinical trial expenses, regulatory efforts, and acquisitions, the company said.

Trovagene separately also said in another SEC document that it has entered into a controlled equity offering sales agreement with Cantor Fitzgerald to offer and sell up to $30 million of its stock through the investment bank.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.